Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients.
Morales-Lara
M J
MJ
Conesa-Zamora
P
P
García-Simón
M S
MS
Pedrero
F
F
Santaclara
V
V
Perez-Guillermo
M
M
Soriano-Navarro
E
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D056726:Genetic Association Studies; D006801:Humans; D000069285:Infliximab; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000235:genetics
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000069285:Infliximab